Skip to main content

Table 4 Costs and QALY estimates for the three scenarios considered in the cost-utility analysis

From: A cluster randomised control trial to evaluate the effectiveness and cost-effectiveness of the Italian medicines use review (I-MUR) for asthma patients

  Intervention (N = 600) Control (N = 663) p-value
Mean Sd Mean Sd P
Scenario 1: 3 months
 Difference in yearly patient costs between T3 and T0 (public healthcare perspective, [13] Euros 2015) −122.63 747.03 −113.29 828.04 0.01
 Difference in yearly patient costs between T3 and T0 (societal perspective, [6] Euros 2015) −95.17 660.94 −95.82 741.32 0.01
 Difference1 in QALYs between T3 and T0 [39] 0.02 0.10 0.01 0.10 0.86
Scenario 2: 6 months
 Difference in yearly patient costs between T6 and T0 (public healthcare, [13] Euros 2015) −154.84 846.47 −113.29 828.04 0.01
 Difference in yearly patient costs between T6 and T0 (societal perspective, [6] Euros 2015) −115.93 741.45 −95.82 741.32 0.01
 Difference in QALY s between T6 and T0 [39] 0.03 0.12 0.01 0.10 0.01
Scenario 3: 9 months
 Difference in yearly patient costs between T9 and T0 (public healthcare perspective, [13] Euros 2015) −207.04 828.88 −113.29 828.04 0.01
 Difference in yearly patient costs between T9 and T0 (societal perspective [6] Euros 2015) −158.56 729.97 −96.12 741.37 0.01
 Difference in QALYs between T9 and T0 [39] 0.04 0.11 0.01 0.10 0.01